Clinical Trial Update: P-PSMA-101 CAR-T Cells in the Treatment of Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC) and Advanced Salivary Gland Cancers (SGC) [Phase 1]

View source ↗

Summary

Poseida Therapeutics conducted a Phase 1 trial of P-PSMA-101 CAR-T cells in metastatic castration-resistant prostate cancer and advanced salivary gland cancers.…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acinic Cell Carcinoma
• Adenoid Cystic Carcinoma
• Castration-resistant Prostate Cancer
• Mucoepidermoid Carcinoma
• Salivary Duct Carcinoma
• Salivary Gland Cancer

Drugs mentioned

• P-PSMA-101 CAR-T cells

Snippet

Sponsor: Poseida Therapeutics, Inc. | Conditions: Prostatic Neoplasms, Castration-Resistant, Neoplasms by Histologic Type | Phase 1 | Status: TERMINATED